Overview and Scope
The digestive and intestinal remedy refers to medications that can treat gastrointestinal disorders such as stomach upset, constipation, and diarrhoea. It uses classes of drugs such as antacids, proton pump inhibitors, and histamine2 blockers during the treatment process.
Sizing and Forecast
The digestive and intestinal remedies market size has grown strongly in recent years. It will grow from $20.51 billion in 2023 to $21.63 billion in 2024 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to traditional remedies, lifestyle changes, increased stress levels, dietary shifts, covid-19 impact.
The digestive and intestinal remedies market size is expected to see strong growth in the next few years. It will grow to $27.36 billion in 2028 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to healthcare accessibility, global health events, rising health consciousness, ageing population, innovative product development.. Major trends in the forecast period include healthcare access, environmental factors, consumer education, regulatory environment, pharmaceutical advancements.
To access more details regarding this report, visit the link:
Segmentation & Regional Insights
The digestive and intestinal remedies market covered in this report is segmented –
1) By Type: Digestive Medicines, Remedies Against Gastrointestinal Complaints, Natural And Synthetic Agents
2) By Age Group: Pediatric, Adults
3) By Distribution Channel: Online, Offline
North America was the largest region in the digestive and intestinal remedies market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digestive and intestinal remedies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8184&type=smp
Major Driver Impacting Market Growth
The increase in gastrointestinal disorder cases is expected to propel the digestive and intestinal remedy market going forward. Gastrointestinal disorders refer to a collective term of diseases such as nausea, vomiting, food poisoning, and diarrhea that impact the overall biological functioning of the gastrointestinal (GI) tract. The rising incidence of gastrointestinal disorders has resulted in a growing demand for digestive and intestinal remedies that can treat gastrointestinal diseases effectively. For instance, in May 2021, according to a report published by BioMed Central, a UK-based journal, the prevalence of Inflammatory Bowel Disease (IBD) is expected to significantly increase in various regions in 2035. Iran is projected to experience a 2.5-fold rise, reaching 69 thousand cases. In North Africa and the Middle East, the prevalence is estimated to increase by 2.3-fold, totaling 220 thousand cases. Moreover, there is an anticipation of a fourfold increase in prevalence in India, totaling 2.2 million cases. The East Asia region is anticipated to experience a 1.5-fold increase, reaching 4.5 million cases, while high-income Asia-Pacific and Southeast Asia regions are expected to have a 1.6-fold elevation in prevalence, with 183 thousand and 199 thousand cases, respectively. Therefore, an increase in gastrointestinal disorder cases is expected to drive the growth of the digestive and intestinal remedy market.
Key Industry Players
Major companies operating in the digestive and intestinal remedies market report are Bayer AG, Abbott Laboratories, Bausch Health Companies Inc., CH Boehringer Sohn AG & Co. KG, Eli Lilly and Company, GlaxoSmithKline plc, Jiangzhong Pharmaceutical Co. Ltd., Johnson & Johnson Pvt. Ltd., Menarini Group, Merck Co. & KGaA, Pfizer Inc., Prestige Consumer Healthcare Inc., Procter & Gamble Company, Reckitt Benckiser Group plc, Sanofi SA, Takeda Pharmaceutical Company Limited, AbbVie Inc., Alfa Wassermann and Sigma-Tau, Allergan plc, AstraZeneca plc, Boehringer Ingelheim International GmbH, Daiichi Sankyo Chemical Pharma Co. Ltd., Evoke Pharma Inc., Ipsen SA, Ironwood Pharmaceuticals Inc., Mundipharma, Mylan NV, Norgine Pharmaceuticals Ltd., Novartis AG, Otsuka Pharmaceutical Co. Ltd., Perrigo Company, Recordati S.p.A., RedHill Biopharma Ltd., Ritter Pharmaceuticals Inc., Salix Pharmaceuticals Inc.
The digestive and intestinal remedies market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
